Literature DB >> 27990076

Daclatasvir (Daklinza): A Treatment Option for Chronic Hepatitis C Infection.

Maggie Montgomery, Natalie Ho, Elizabeth Chung, Nino Marzella.   

Abstract

Daclatasvir (Daklinza) for chronic hepatitis C infection.

Entities:  

Year:  2016        PMID： 27990076      PMCID： PMC5132415     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  9 in total

Review 1.  New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.

Authors:  Sean M McConachie; Sheila M Wilhelm; Pramodini B Kale-Pradhan
Journal:  Expert Rev Clin Pharmacol       Date:  2016-01-08       Impact factor: 5.045

Review 2.  Antiviral resistance and direct-acting antiviral agents for HCV.

Authors:  Amanda L Aloia; Stephen Locarnini; Michael R Beard
Journal:  Antivir Ther       Date:  2012-10-05

3.  Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes.

Authors:  Laura E Connell; Hamisu M Salihu; Jason L Salemi; Euna M August; Hanna Weldeselasse; Alfred K Mbah
Journal:  Liver Int       Date:  2011-06-07       Impact factor: 5.828

Review 4.  Hepatitis B and C in pregnancy: a review and recommendations for care.

Authors:  J C Dunkelberg; E M F Berkley; K W Thiel; K K Leslie
Journal:  J Perinatol       Date:  2014-09-18       Impact factor: 2.521

Review 5.  Treating viral hepatitis C: efficacy, side effects, and complications.

Authors:  M P Manns; H Wedemeyer; M Cornberg
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

6.  Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  David L Wyles; Peter J Ruane; Mark S Sulkowski; Douglas Dieterich; Anne Luetkemeyer; Timothy R Morgan; Kenneth E Sherman; Robin Dretler; Dawn Fishbein; Joseph C Gathe; Sarah Henn; Federico Hinestrosa; Charles Huynh; Cheryl McDonald; Anthony Mills; Edgar Turner Overton; Moti Ramgopal; Bruce Rashbaum; Graham Ray; Anthony Scarsella; Joseph Yozviak; Fiona McPhee; Zhaohui Liu; Eric Hughes; Philip D Yin; Stephanie Noviello; Peter Ackerman
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

7.  Pegylated interferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Emilio Palumbo
Journal:  Ther Adv Chronic Dis       Date:  2011-01       Impact factor: 5.091

8.  Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.

Authors:  Zulema Plaza; Vincent Soriano; Eugenia Vispo; Maria del Mar Gonzalez; Pablo Barreiro; Eduardo Seclén; Eva Poveda
Journal:  Antivir Ther       Date:  2012-03-21

9.  All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Authors:  David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425
  9 in total
  1 in total

Review 1.  Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study.

Authors:  Mahmoud H Teaima; Adi Al-Nuseirat; Dalia Abouhussein; Osama A Badary; Mohamed A El-Nabarawi
Journal:  J Pharm Policy Pract       Date:  2021-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.